Table 1.
In vitro activity of ceftolozane–tazobactam against clinical isolates from intra-abdominal and urinary tract infections
| Source | Pathogen | Number of isolates | TOL/TAZ MIC50 (µg/mL; range) | TOL/TAZ MIC90 (µg/mL; range) | TOL/TAZ S%a |
|---|---|---|---|---|---|
| Aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in hospitals in Europe and the USA (2012)29 | Escherichia coli | 1,674 | 0.25 | 0.5 | 98.5–99.9 |
| MDR E. coli | 85 | 0.5 | 2 to >32 | 75–98.6 | |
| K. pneumoniae | 442 | 0.25 | 16 | 88.9–89.6 | |
| MDR K. pneumoniae | 78 | 16 | >32 | NR | |
| Enterobacter spp. | 228 | 0.25–0.5 | 4–8 | NR | |
| Citrobacter spp. | 113 | 0.25 | 2 | NR | |
| Proteus mirabilis | 117 | 0.5 | 0.5 | NR | |
| P. aeruginosa | 327 | 0.5 | 4 | 93.4–95.7 | |
| MDR P. aeruginosa | 59 | 2–4 | >32 | 65–73.7 | |
| XDR P. aeruginosa | 43 | 4–8 | >32 | 56.7–61.5 | |
| CAZ-NS P. aeruginosa | 61 | 2–4 | >32 | 60–80.8 | |
| MEM-NS P. aeruginosa | 77 | 2 | >32 | 75.5–79.2 | |
| Pathogen | Number of isolates | TOL/TAZ MIC50 (µg/mL) | TOL/TAZ MIC90 (µg/mL) | TOL/TAZ S% (CLSI/EUCAST) | |
| Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intra-abdominal infections in Europe (2012–2015)30 | Enterobacteriaceae | 5,950 | 0.25 | 1 | 93.5/91.3 |
| ESBL non-CRE phenotype | 906 | 0.5 | 8 | 82.8/74.9 | |
| Escherichia coli | 3,460 | 0.25 | 0.5 | 98.8/98 | |
| ESBL non-CRE phenotype | 559 | 0.5 | 2 | 92.7/87.8 | |
| K. pneumoniae | 917 | 0.25 | >32 | 79.3/75.8 | |
| ESBL phenotype | 373 | 4 | >32 | 49.1/41.6 | |
| ESBL non-CRE phenotype | 280 | 1 | >32 | 65.4/55.4 | |
| Enterobacter spp. | 432 | 0.5 | 8 | 78/69.7 | |
| Enterobacter cloacae | 278 | 0.5 | 16 | 76.6/70.1 | |
| Citrobacter koseri | 101 | 0.25 | 0.5 | 100/100 | |
| Citrobacter freundii | 111 | 0.25 | 8 | 79.3/78.4 | |
| P. mirabilis | 368 | 0.5 | 0.5 | 97.3/95.7 | |
| ESBL phenotype | 32 | 1 | 8 | 71.9/56.2 | |
| Indole-positive Proteeae | 237 | 0.25 | 1 | 97.5/94.9 | |
| Serratia spp. | 77 | 0.5 | 2 | 98.7/88.3 | |
| P. aeruginosa | 603 | 0.5 | 4 | 91.7/91.7 | |
| CAZ-NS P. aeruginosa | 139 | 4 | >32 | 65.5/65.5 | |
| MEM-NS P. aeruginosa | 126 | 2 | >32 | 65.9/65.9 | |
| PIP/TAZ-NS P. aeruginosa | 162 | 2 | >32 | 70.4/70.4 |
Notes: aPercentage of isolates inhibited at an MIC of ceftolozane-tazobactam of ≤8 mg/L. Adapted with permission from Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69(3):266–277. Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.29 And from: Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosacausing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother. 2017;72(5):1386–1395. © The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.30
Abbreviations: TOL/TAZ, ceftolozane–tazobactam; MIC, minimum inhibitory concentration; S, susceptible; MDR, multidrug-resistant; XDR, extensively drug-resistant; CAZ-NS, ceftazidime-non-susceptible; MEM-NS, meropenem-non-susceptible; ESBL, extended-spectrum β-lactamase; CRE, carbapenem-resistant Enterobacteriaceae; PIP/TAZ-NS, piperacillin–tazobactam-non-susceptible.